Monoclonal antibodies (MAbs) were prepared against avian metapneumovirus (aMPV) subtype C (aMPV/ Minnesota/turkey/1a/97). Six MAbs were selected based on enzyme-linked immunosorbent assay activities and characterized by isotyping, neutralization test, western blot analysis, and immunohistochemistry assay. The results showed that three MAbs (3E, 9D, and 12C) belonged to the IgG1 subclass, whereas the other three (5D, 8E, and 16E) were of the IgG2a subclass. None of the six MAbs neutralized aMPV infectivity at a detectable level, but all reacted with both denatured and nondenatured forms of the nucleocapsid (N) protein of aMPV, suggesting that these MAbs may recognize structurally independent epitopes of the N protein. These MAbs provide new tools and methods for investigating aMPV infection and pathogenesis, as well as diagnosis of aMPV disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1637/7513-020606R.1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nuclear Magnetic Resonance Study of Monoclonal Antibodies Near an Oil-Water Interface.
J Pharm Sci
January 2025
Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Tallahassee, FL, USA, 32310; Center for Interdisciplinary Magnetic Resonance, National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL, USA, 32310. Electronic address:
Monoclonal antibodies (mAb) represent an important class of biologic therapeutics that can treat a variety of diseases including cancer, autoimmune disorders or respiratory conditions (e.g. COVID-19).
View Article and Find Full Text PDFA novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins.
Sci Rep
January 2025
Johnson & Johnson, Therapeutics Discovery, Spring House, PA, USA.
Solution-based affinity assays are used for the selection and characterization of proteins that could be developed into therapeutic molecules. However, these assays have limitations for cell-surface proteins as in most cases their purification requires detergent solubilization and are unlikely to assume conformations in solution that resemble their native states in cell membranes. This report describes a novel electrochemiluminescence-based method, called MSD-CAT, for the affinity analysis of antibodies binding to cell-surface receptors.
View Article and Find Full Text PDFRosacea-like skin reaction under treatment with dupilumab for atopic dermatitis.
J Dermatolog Treat
December 2025
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Purpose: Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.
Material And Methods: This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis.
How to: share and reuse data - challenges and solutions from PrIMAVeRa project.
Clin Microbiol Infect
January 2025
Infectious Diseases and Microbiology Division, Hospital Universitario Virgen Macarena; Department of Medicine, University of Seville; Instituto de Biomedicina de Sevilla (IBiS)/Consejo Superior de Investigaciones Científicas (CSIC), Seville, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Background: Data sharing accelerates scientific progress and improves evidence quality. Even though journals and funding institutions require investigators to share data, only a small part of studies made their data publicly available upon publication. The procedures necessary to share retrospective data for re-use in secondary data analysis projects can be cumbersome.
View Article and Find Full Text PDFCorrelates of Cetuximab Efficacy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Previously Treated With Immunotherapy.
JCO Precis Oncol
January 2025
Department of Medicine, Massachusetts General Hospital, Boston, MA.
Purpose: Immune checkpoint inhibitors (ICIs) are now first-line therapy for most patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), and cetuximab is most often used as subsequent therapy. However, data describing cetuximab efficacy in the post-ICI setting are limited.
Methods: We performed a single-institution retrospective analysis of patients with R/M HNSCC treated with cetuximab, either as monotherapy or in combination with chemotherapy, after receiving an ICI.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!